Gilead’s Magrolimab Mostly Back On Track As FDA Lifts AML, MDS Holds

 
• By Alaric DeArment

The clinical holds, initially announced in January, raised concerns about the company losing its edge in CD47-targeting drugs. Partial holds on the DLBCL and myeloma programs remain in place.

Gilead's magrolimab is mostly back on track after the FDA lifted a partial hold on two key indications • Source: Alamy

More from Clinical Trials

More from R&D